USD10
ALLO acciones
Acerca de Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
USD10
ALLO acciones
Acerca de Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Estadísticas
VENTANA DE OPERACIÓN
Cerrado
ABRE A LAS
No hay suficientes datos
CAPITALIZACIÓN DE MERCADO
476,43 M US$
PRECIO DE APERTURA
2,23 US$
BAJO (1Y)
0,8621 US$
ALTO (1Y)
2,80 US$
BAJO (24H)
2,06 US$
Alza (24H)
2,26 US$
Volumen (24 h)
20,75 M US$
516,04 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | 2,23 US$ | |
1 día | 2,23 US$ | |
1 semana | 2,44 US$ | |
1 mes | 2,10 US$ | |
1 año | 1,68 US$ |